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Abstract 
The switch from in situ to invasive tumor growth represents a crucial stage in the 
evolution of lung adenocarcinoma. The biological understanding of this shift is limited 
however and ‘Noguchi Type C’ tumors, being early lung adenocarcinomas with 
mixed in situ and invasive growth, represent those which are highly valuable in 
advancing our understanding of this process. 
All Noguchi Type C adenocarcinomas (n=110) from the LATTICE-A cohort were 
reviewed and two patterns of in situ tumor growth were identified; those deemed 
likely to represent a true shift from precursor in situ to invasive disease (‘Noguchi 
C1’) and those in which the lepidic component appeared to represent outgrowth of 
the invasive tumor along existing airspaces (‘Noguchi C2’). Overall Ki67 fraction was 
greater in C2 tumors and only C1 tumors showed significant increasing Ki67 from in 
situ to invasive disease.  P53 positivity was acquired from in situ to invasive disease 
in C1 tumors but both components were positive in C2 tumors. Likewise vimentin 
expression was increased from in situ to invasive tumor in C1 tumors only. Targeted 
next generation sequencing of 18 C1 tumors identified four mutations private to the 
invasive regions, including two in TP53, while 6 C2 tumors showed no private 
mutations. In the full LATTICe-A cohort, Ki67 fraction classified as either less than or 
greater than 10% within the in situ component of lung adenocarcinoma was identified 
as a strong predictor of patient outcome. This supports the proposition that tumors of 
all stages which have ‘high grade’ in situ components represent those with 
aggressive lepidic growth of the invasive clone.  
Overall these data support that the combined growth of Noguchi C tumors can 
represent two differing biological states and that ‘Noguchi C1’ tumors represent the 
genuine biological shift from in situ to invasive disease 
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Introduction 
Invasive carcinomas of the lung arise from in situ precursors (1). When precursor 
cells invade across the basement membrane, they gain access to interstitial tissue 
and to vascular structures, enabling distant metastasis. This switch from in situ to 
invasive growth is crucial in the development of lethal tumors, and presents a 
tempting target for prevention or intervention, especially in high-risk groups. 
In comparison to other common adenocarcinomas, pre-invasive lung lesions have 
proved difficult to characterise. They can only be accessed following invasive 
surgery, and the majority of resected tumors are very advanced, in biological terms, 
and already show widespread invasive behaviour. Nonetheless, there is a well-
described histopathological continuum of lesions from atypical adenomatous 
hyperplasia, through adenocarcinoma in situ, then minimally invasive 
adenocarcinoma, and finally to extensively invasive disease, and this has been 
adopted into the pathological criteria for diagnosis defined by the WHO and IASLC 
(2). This morphological classification is highly prognostic, and tumors with no 
evidence of invasion have very low rates of nodal metastasis, and very good 
outcomes post-surgery (3). However, in comparison to other common malignancies, 
this ‘Vogelgram’ is not yet accompanied by a detailed catalogue of driving genomic 
changes. Our current knowledge is predominantly based on studies that compare 
invasive and in situ tumors (4-6) which show EGFR amplification copy number gain, 
TP53 mutation and increasing chromosomal instability identified as genomic 
changes associated with invasive tumors. More recent large-scale studies have 
generated illuminating data on tumor evolution by the multiregional sequencing of 
invasive tumors and metastases (7,8). Few studies however have as yet shown 
evidence of molecular progression from histologically defined in situ to invasive 
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growth within individual tumors. What data there is shows EGFR amplification and 
increasing chromosomal rearrangements to be the most conclusively defined 
changes seen in the transition from in situ to invasive disease (9,10). This kind of 
evidence is vital, as it directly links genomic events to cell biology in single tumors, 
giving concrete examples of the diverse routes to invasiveness taken by single tumor 
clones under the influence of natural selection. 
We therefore set out to use a rigorous microscopic histopathological approach to 
identify mutations which are found only in invasive parts of very early lung 
adenocarcinomas, simultaneously aiming to improve our understanding of tumor 
morphology in these cancers. 
This approach required the identification of early adenocarcinomas containing both 
areas of in situ precursor and more advanced invasive disease. In living patients this 
stage is likely to be transient; even small tumors can be wholly invasive, as the 
aggressive, biologically advanced invasive component often quickly overwhelms the 
in situ precursor. For this reason, it is necessary to examine large numbers of 
archival tumors to identify those which show both precursor and invasive modes of 
growth. 
The study performed by Noguchi et al in 1995 is perhaps the most influential 
investigation of morphological progression in lung cancer (11). In this landmark 
paper, it was shown that clinically early (<20mm) tumors could be meaningfully 
separated into 6 classes designated A-F: A are wholly in situ, B are biologically in 
situ with areas of stromal alteration morphologically mimicking invasion 
(‘pseudoinvasion’), C are of mixed in situ and invasive patterns, and D-F are wholly 
invasive. The four classes are impressively diverse in their survival outcomes, and a 
descendent of this morphological approach has been incorporated into the current 
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WHO tumor classification and cancer staging. “Noguchi C” lesions present us with 
an opportunity to sequence in situ and invasive areas from the same tumor, with the 
hope of identifying associated DNA changes. 
However, we believed it probable that not all type C lesions were suitable for the 
detection of biological progression. It is known that invasion-competent cells can 
sometimes grow in a lepidic manner, as is sometimes seen in invasive tumors which 
have metastasised to the lung from other primary organs (12,13). This therefore 
raises the possibility that primary lung adenocarcinoma cells with invasive potential 
may also opportunistically grow lepidically, giving an in situ appearance. In the same 
way that Noguchi et al morphologically separate true invasion from pseudoinvasion 
by separating class B from class C, we suggest that it is possible to morphologically 
separate true precursor in situ growth from biologically advanced in situ growth by 
criteria which are detailed below. Retaining the Noguchi letter classification, we 
name these two classes C1 and C2: Noguchi C1 tumors are truly biologically 
biphasic, with a ‘precursor’ in situ component and the potential to reveal genomic 
changes which drive invasion, while in Noguchi C2 tumors, the in situ component 
represents opportunistic in situ/lepidic outgrowth by an invasion-competent clone of 
cells. This carries important clinical implications, as the recognition of in situ growth 
patterns with very different invasion potential may alter the interpretation of biopsies 
containing only in situ tumor, or of high-resolution CT imaging showing ground glass 
changes suggestive of in situ tumor growth. 
In this way we identified numerous C1 and C2 lesions from our historical cohort of 
994 primary lung adenocarcinomas. We constructed focussed tissue microarrays of 
in situ and invasive areas from these tumors for quantitative in situ assays of 
proliferation and p53 expression. Furthermore, in order to detect genomic changes 
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related to step changes in tumor morphology, we performed laser capture 
microdissection of neighbouring epithelial areas followed by DNA extraction and 
next-generation sequencing of a panel of cancer driving genes. 
Methods 
For this study we interrogated a 994 patient retrospective cohort of resected lung 
adenocarcinomas for which comprehensive clinicopathological data including 
survival information has been collated (LATTICe-A: Leicester Archival Thoracic 
Tumor Investigatory Cohort – Adenocarcinoma). This study was approved by The 
Northampton Research Ethics Committee (reference 14/EM/1159) and University 
Hospitals Leicester NHS Trust Research and Innovation Department (reference UHL 
11363). The cohort includes all resected primary adenocarcinomas from our surgical 
centre from 1998-2014. Nodal invasion status was collected from histopathology 
reports. Patient outcomes were obtained from local and national databases. 
Morphological classification 
242 tumors ≤20mm were examined. Scanned digital images (Hamamatsu 
Nanozoomer) of all original diagnostic slides were reviewed by 2 subspecialist 
thoracic histopathologists (DM and JLQ) and classified as per Noguchi et al. (11). 
The pathologists were blinded to the clinical outcome data. 
110 Noguchi C tumors were identified, defined as tumors with areas of lepidic growth 
and ‘true’ invasion with fibroblastic stromal changes. Noguchi C tumors were 
subclassified into class C1 (precursor) and C2 (outgrowth) patterns on morphological 
grounds: we applied a simple score to each tumor, giving one point each for 
observation of: i) clear nuclear grade difference (size/shape/pleomorphism) between 
the in situ and invasive components, ii) architectural asymmetry reflecting the 
centrality of the invasive component and iii) the absence of an in situ ‘penumbra’, 
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with penumbra referring an in situ component of uniform width at the edge of the 
lesion (Figure 1A). Tumors scoring 3 or 2 were classified as ‘Noguchi C1’, while 
those scoring 1 or 0 were classified as ‘Noguchi C2’. Examples of each type are 
shown in Figure 1B. 
Tissue Microarray construction 
Two tissue microarray series were constructed, the first was a focused Noguchi C 
microarray containing 44 tumors, the second was an entire lung adenocarcinoma 
cohort microarray  containing 966 tumors.  
The Noguchi C tissue microarray was constructed from all Noguchi C tumors with 
sufficient tissue available. 27 C1 and 17 C2 tumors were included. For each tumor, 2 
x 1mm cores of invasive tumor and 2x 1mm cores of in situ tumor were taken. 
The full LATTICe-A cohort tissue microarray consisted of  966 tumors from a 994 
tumor cohort. 3x1mm cores were obtained from each case. Where possible, cores 
were taken from different donor blocks, and were selected to maximise sampling of 
observed variance in tumor pattern. In particular, where possible, both in situ and 
invasive regions were sampled. Core sampling was directed by examination of 
scanned whole section H&E images and correspondence to paraffin blocks. 
Recipient blocks contain either 60 or 40 cases (ie 180 or 120 tumor cores) plus 
orientation and control cores. The entire cohort is represented in 22 tissue 
microarrays. All tissue microarrays were constructed in quadruplicate using a semi-
automated TMArrayer (Pathology Devices). Sections were stained with H&E, and 
all cores were assigned a growth pattern as per IASLC recommendations (2). 
Immunohistochemistry 
Immunohistochemistry for Ki67, p53 and vimentin was applied to the Noguchi C 
tissue microarray. This was performed following use of the Dako Target Retrieval 
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Solution pH9, S2375, in a PTLink at 97 degrees for 20 minutes. The antibodies Ki-67 
IR622, p53 IR616 and Vim IR630 were applied and visualised using Dako Flex+ kit 
K8002, on a Dako Link48 Autostainer. Ki67 staining was also applied to the full 
LATTICE cohort tissue microarray using the same method. 
Manual scoring was performed for all 3 stains. Ki67 was scored as a % of nuclear 
positivity within tumor cells. Scoring for nuclear tumor cell p53 staining was 
performed as previously described for the reporting of mutant status in lung 
adenocarcinoma (14). Vimentin expression in tumor cell was quantified using H 
score method (0-300). Individual cores were scored and the mean was taken across 
cores from a single tumor to determine the whole tumor values. 
ALK and ROS1 rearrangement testing was applied to whole sections from the 
Noguchi C next generation sequencing series only. The Ventana ALK (D5F3) 
immunohistochemistry assay and Cell Signalling Technology ROS1 (D4D6) assay 
were used. Both were applied on the Ventana Ultra platform within a clinically 
accredited molecular pathology laboratory.Laser capture microdissection 
18 C1 tumors and 5 C2 tumors with sufficient residual tissue in the resection blocks 
following tissue microarray construction underwent laser capture microdissection 
(LCM) using the Zeiss PALM system to separately sample the in situ and invasive 
components. Serial 10 micron sections were cut from the formalin fixed paraffin 
embedded block, dewaxed and stained with cresyl violet. 4 to 10 sections were used 
for microdissection. DNA was extracted using the Qiagen Generead FFPE DNA 
extraction kit, producing DNA quantities following extraction of 20-5000ng. Germline 
DNA was extracted from uninvolved lymph node tissue.  
Next generation sequencing 
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All samples generated underwent library preparation and targeted next generation 
sequencing using the Life Technologies Lung and Colon Cancer Panel on an 
IonTorrent Personal Genome Machine using 10ng of extracted DNA. This gene 
panel covers commonly mutated regions of 22 lung and colon cancer associated 
genes. Driving mutations were identified using the Life Technology Variant Caller 
software and were identified as either being shared between the invasive and in situ 
components or private to one of the regions. Full details of the amplicons covered by 
this gene panel are given in supplementary data file 1. 
Statistical methods 
Following the use of Shapiro Wilk test of normality for Ki67 and vimentin scores, 
comparisons between C1 and C2 tumors were performed using the Mann-Whitney 
test, and between in situ and invasive components of the same tumor using the 
Wilcoxon Signed-Rank test.  Due to the binary nature of the p53 scores, 
comparisons between C1 and C2 tumors were performed using the Pearson chi-
squared test, and between in situ and invasive components of the same tumor using 
McNemar’s test. Survival analysis was performed using Kaplan-Meier methods, and 
significance of difference between groups was assessed by the log-rank test.  All 
survival analysis used an Overall Survival model, which records all patient deaths as 
events and censors other patients at their last visit date.  All statistical analysis was 
performed using Stata/SE 15.1. 
Results         
Morphological Noguchi C Tumor Assessment.  
242 adenocarcinomas from the LATTICe-A cohort (n= 994) were 20mm or less in 
size. On pathological review 110 showed both invasive and in situ disease and were 
therefore classified as Noguchi type C tumors. 
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Inspection of the Noguchi C tumors revealed two distinct classes based on the 
appearance of the in situ component. One class of lesions had little symmetry and 
often showed a higher nuclear grade in the invasive area. We hypothesised that 
these tumors were showing true biological progression from a low-grade precursor 
clone to an invasive subclone, and designated them ‘C1’. The other class showed 
more symmetry, with a constant-thickness peripheral zone (or ‘penumbra’) of lepidic 
growth surrounding a zone of invasion, with both the invasive and lepidic cells 
showing similar nuclear features. We hypothesised that in these tumors, the lepidic 
zone represented opportunistic lepidic peripheral outgrowth of an invasion-
competent tumor clone, and designated them ‘C2’. These appearances are 
summarized in Figure 1A & B. This detailed classification scheme was applied to all 
110 Noguchi C tumors, identifying 42 C1 and 68 C2 tumors. The result of this 
scoring is presented in Table 1. Demographic and pathological information for these 
patients is presented in Table 2 and breakdown of tumors types by current WHO 
classification is presented in Table 3. Just over half of the C1 tumors (22/42) were 
lepidic predominant (lepidic predominant adenocarcinoma plus minimally invasive 
adenocarcinoma), whereas only 8 of the 68 C2 tumors fell into either of these 
categories, with the majority representing acinar predominant adenocarcinoma. 
According to our model, C1 tumors were resected when they had only just acquired 
focal invasive capability and would therefore have had limited opportunity for 
metastasis. C2 tumors, however, represent established invasive disease. In support 
of this, the rate of nodal metastasis at resection was significantly higher in C2 tumors 
(26%) than in C1 tumors (8%) (p= 0.03) (Figure 1C), although we did not detect a 
significant difference in patient outcome (Figure 1D). 
Molecular phenotypes of C1 and C2 tumors 
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Within the focused Noguchi C tissue microarray quantitative in situ 
immunohistochemical assays were applied. First, we assessed proliferation rates in 
in situ and invasive parts of both C1 and C2 tumors by Ki67 staining (Figure 2A). C2 
tumors show significantly greater proliferation rates than C1 tumors overall (mean C1 
Ki67 8.9%[±1.6] versus C2 23.3%[±2.8], p<0.0001). Furthermore, the invasive areas 
of C1 tumors are significantly more proliferative than neighbouring in situ areas 
(10.8%[±1.7] vs 7.1%[1.6], p<0.001), while invasive and in situ areas of C2 tumors 
are not significantly different (24.5%[±3.0] vs 22.1%[±2.8], p=0.3). 
The difference in proliferation rate between in situ and invasive regions of C1 tumors 
supports the hypothesis that it is these tumors which are most likely to truly 
represent biological progression. The much higher proliferation rate of in situ growth 
in C2 tumors compared to the in situ growth in C1 strongly supports our hypothesis 
that there are distinct modes of in situ tumor cell proliferation. 
TP53 mutations have previously been linked to biological progression in lung 
adenocarcinoma (14). Therefore, if our classification of C1 tumors is truly identifying 
cases undergoing step progression, then we might expect to find a higher rate of 
mutant p53 in invasive areas of this group. This was assessed in situ by 
immunohistochemical staining to detect the nuclear accumulation of mutant protein.  
C1 tumors showed a lower rate of p53 mutant phenotype positivity than C2 tumors 
overall, although this was not statistically significant. C1 tumors did however show 
the acquisition of p53 positivity in 5 of the 27 tumors assessed representing a 
significant difference between the in situ and invasive (P<0.05), while all C2 tumors 
positive in the invasive component were also positive in the in situ component (figure 
2B). 
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Finally, we assessed the expression of vimentin as a marker of epithelial-
mesenchymal transition, which is associated with the switch to invasiveness in many 
solid tumors (15,16). Invasive tumor areas showed greater vimentin expression 
compared to adjacent in situ regions in C1 tumors (mean H score 88.8[±23.1] versus 
31.4[±13.8], p<0.01), with no significant difference in C2 tumors (figure 2C). 
Representative tissue microarraycore images from the staining of all 3 antibodies are 
shown in figure 3.   
Targeted Next Generation Sequencing 
To identify genomic mutations driving invasiveness in early lung adenocarcinomas, 
18 C1 tumors were subjected to targeted next generation sequencing of both in situ 
and invasive areas. We also subjected 5 C2 tumors to sequencing in order to test 
our hypothesis that in these tumors, in situ growth is in fact facultative surface 
outgrowth of highly transformed cells with the biological ability to invade. In every 
case, microscopically identified in situ and invasive epithelial cells were dissected out 
by laser capture microdissection prior to panel DNA sequencing. Sequence data are 
summarised in Figure 4. 
Taking the 23 tumors together, mutations in KRAS, EGFR and BRAF were 
ubiquitous; one of the genes carried a driver mutation in 74% of this small cohort. In 
every case, these mutations were shared by both in situ and invasive areas, 
indicating that they are extremely early events, occurring during the pre-invasive 
stage of tumor development. 
The 18 C1 lesions yielded a total of 20 somatic mutations, and only 3 tumors did not 
contain detectable mutations. 3 tumors had mutations which were private to the 
invasive portion of the tumor, and which are therefore likely to be driving invasive 
behaviour. Invasion-specific TP53 mutations were present in 2 of these cases, one 
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of which harboured a second invasion-private mutation in PIK3CA. The third case 
had an invasion-private mutation in SMAD4. Crucially, no mutations were private to 
in situ regions. 
A total of 9 mutations were identified in the 5 C2 tumors, with all tumors showing at 
least one mutation. All mutations were shared between in situ and invasive regions. 
Even with the limitations of a small sample size the difference in the overall rate of 
TP53 mutations between the C1 (17%) and C2 tumors (80%) was statistically 
significant (p=0.006). Furthermore, two of the three TP53 mutations in C1 lesions 
were private to the invasive component, so the difference in rate of TP53 mutations 
in C1 and C2 in situ tumor areas was even greater (6% to 80%, p=0.0004). This 
concurs with the immunohistochemical assay for mutant p53 protein, and further 
supports the idea that C2-type in situ growth is biologically different from that seen in 
C1 tumors. 
Full details of the variants called are given in supplementary data file 2. 
For completion all tumors tested by next generation sequencing were also assessed 
for ALK and ROS1 driver rearrangements. Both assays were negative in all cases 
tested. One case was not tested due to a lack of residual archival tissue (C1_NGS9), 
although this case showed an exon 19 EGFR deletion on next generation 
sequencing analysis.  
Prognostic power of Ki-67 in in situ tumor areas 
Having observed that in situ/lepidic tumor growth can be of two distinct biological 
different types, ‘precursor’ (as seen in C1 tumors) and ‘outgrowth’ (as seen in C2), 
and that these are measurably different in their proliferation rates, we set out to test 
the hypothesis that precursor type in situ growth is prognostically distinct from 
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invasive type in situ growth in a large set of adenocarcinomas regardless of subtype 
or stage. 
To achieve this, we assessed the Ki67-positive proliferative fraction of tumor cells in 
tissue microarrays constructed from our entire cohort of 994 adenocarcinoma 
patients with 3 cores per patient. Individual cores were morphologically classified as 
being of in situ or invasive growth pattern. For each case, we calculated a median 
proliferation score for in situ cores, or for invasive cores, or in cases where both 
patterns were represented in the microarray, for both areas. 756 of these cases had 
an invasive pattern core scored for Ki67 % and were eligible for survival analysis. 
143 of these cases had an in situ pattern core scored for Ki67 % and were eligible 
for survival analysis.  
In order to identify a rational cut-off to separate biologically preinvasive tumor from 
invasive tumor outgrowth we compared proliferation rates in in situ areas from C1 
precursor and C2 outgrowth tumors using the focussed tissue microarray data 
described above (figure 5A). A proliferation fraction of around 10% is optimal for 
separating C1 from C2 in situ growth patterns, so this level was used as a cut-off. An 
in situ pattern Ki67-positivity rate ≤10% is therefore most likely to represent 
‘precursor’ pattern, while a score of ≥10% is more likely to represent ‘outgrowth’ 
pattern. 
When these values are entered into Kaplan-Meier survival models, proliferation in in 
situ cores in the tissue microarray is highly prognostic (figure 5C). In contrast, the 
same cut-off applied to proliferation rate in invasive cores is only of borderline 
significance (figure 5B). 
This shows that high- and low- proliferative patterns of in situ growth are strongly 
related to tumor virulence, and we suggest that this is because the ‘outgrowth’ type 
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in situ pattern is likely to reflect nearby invasive disease, whereas ‘precursor’ type 
growth is relatively innocuous, and may be encountered in entirely preinvasive 
lesions. 
Discussion 
A large proportion of resected lung adenocarcinomas contain a proportion of in 
situ/lepidic growth pattern (17). The pattern is easily recognised in tissue sections 
morphologically and is appreciable in in CT imaging as ground glass opacity (18). In 
both histological and radiological studies, a high proportion of in situ pattern or 
ground glass opacity is known to predict relatively good outcome clinically (19), as 
might be expected given that tumor cells in situ are by definition unable to 
metastasize. For this reason, there is a widespread assumption that in situ tumor 
proliferation always represents a precursor to invasive disease. However, there has 
as yet been no systematic investigation of the molecular and/or genomic significance 
of precisely histologically defined in situ growth pattern. 
In this study, we present morphological, immunohistochemical, and genomic 
evidence that in situ growth in partially invasive adenocarcinomas encompasses two 
distinct modes of tumor growth (summarised in table 4). The first is a precursor state, 
in biological terms a relic from before the acquisition of invasive potential, 
encountered in early adenocarcinomas as an invasive clone emerges from it, 
designated in this study as C1 tumors. This is precisely analogous to preinvasive 
lesions seen in other carcinomas, such as Bowen’s disease in the skin or colonic 
adenomas. The second is a high-grade outgrowth of biologically advanced 
malignancy, opportunistically growing on the alveolar surface, in what we designate 
C2 lesions. This appearance of carcinoma in situ seen ‘creeping’ along an epithelial 
surface adjacent to high-grade invasive cancer is a phenomenon commonly 
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observed at the periphery of invasive carcinomas including colorectal, squamous, 
and breast carcinomas. As in other carcinomas, the precursor lesion in lung 
adenocarcinoma is characteristically of lower proliferation rate and nuclear grade 
than more highly transformed in situ lesions.  
Furthermore, we find that the precursor pattern, as judged by proliferation rate, is 
associated with better patient outcomes than the outgrowth pattern across a wider 
cohort of resected adenocarcinomas. That the in situ component Ki67% represents a 
stronger predictor than the same analysis in the invasive component across all 
resected adenocarcinomas may reflect ‘outgrowth’ being a marker of aggressive 
disease in lung adenocarcinoma, regardless of stage and subtype. This distinction is 
of potential clinical importance.  
Whilst it is noted that there is no difference in overall survival difference between C1 
and C2 tumors, this may be limited by sample size. Nodal disease was more 
frequent in C2 tumors and this of course affects overall stage which impacts upon 
survival, though classification of ≤ 20mm adenocarcinomas was performed blinded 
to nodal status. Ideally only tumors with combined lepidic and acinar growth would 
have been included in this study, but such restrictive inclusion would have limited 
this to a far less meaningful cohort of only 20 cases. 
Proportional growth pattern scoring is now a central part of tumor classification under 
the WHO diagnostic guidelines, and is known to be highly prognostic (20,21). The 
separation of in situ growth into two categories might improve this further. For 
example, in small biopsies, it is not uncommon only to receive a fragment of tumor 
displaying in situ growth. Our data suggest that in these circumstances proliferation 
rate might usefully separate precursor lesions from outgrowth from invasive cancer, 
with associated prognostic impact. Furthermore, it may be possible to prognostically 
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separate precursor from outgrowth patterns by measurement of metabolic activity by 
positron emission tomography-CT in ground glass opacities. 
Our collection of genomic data was limited in size, both because appropriate lesions 
are rare, and due to the exacting nature of such careful microdissection.  Invasion-
private mutations were detected in 3 of 18 C1 tumors sequenced. In the 5 C2 tumors 
analysed, no genomic progression was identified between in situ and invasive 
elements. The 23 cases sequenced support our model, although definitive 
conclusions cannot be drawn from a series of this size. The tumors sequenced were 
skewed toward C1 lesions in order to meet the wider objective of identifying genomic 
step changes, although a wider sample of C2 tumors and broader sequencing would 
inform this further. In addition, further analyses such as spatial transcriptomics may 
more accurately determine whether the morphological step changes seen in C1 
tumors is genuine cause of invasive phenotype. While not feasible on this archival 
series this may be possible in other studies with optimal tumor material. 
Driving mutations in 5 genes were observed in more than one case: KRAS, BRAF, 
EGFR, TP53, and PIK3CA. KRAS, BRAF and EGFR mutations were always shared 
between in situ and invasive areas, implying very early roles in the progression of 
pre-invasive disease, and confirming their status as classic truncal events. This 
reduplicates the early (i.e. pre genome doubling) timing of these invents as inferred 
from genomic data in the TRACERx study (7). We found that TP53 mutations were 
private to invasive areas in two cases, supporting a wealth of cell biological and 
mouse model evidence that links TP53 to invasive behaviour (4,6,22,23). However, 
we also identified an area of in situ proliferation harbouring TP53 mutations, in case 
11, a mixed-pattern adenocarcinoma. TP53 mutation is not, therefore, sufficient to 
compel invasive behaviour in human lung tissue. 4 cases of the series of 23 (17%) 
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showed no somatic mutation. This is in line with a large cohort of lung cancers tested 
with the same gene panel (24). 
The remaining invasion-private driver mutations were in SMAD4 and PIK3CA, 
implicating a causal role for dysregulation of these pathways in invasive behaviour. 
Activating PIK3CA mutations are not uncommon in lung cancer (25,26), and have 
previously been shown to drive invasive behaviour in colon cancer cells (27) and to 
favour epithelial mesenchymal transition in a mouse model of breast cancer (28), but 
this is the first direct demonstration of PIK3CA mutation being related to a switch to 
invasive behaviour in human lung cancer. SMAD4 loss, while most well known in the 
context of gastrointestinal malignancy, is rarely seen in lung adenocarcinomas 
(7,24), although it has previously been described as a late event (7). 
These data show a very few of the probable plethora of pathways by which natural 
selection can generate invasive behaviour in lung adenocarcinoma, most of which 
remain undescribed. We think it likely that many of our C1 cases would show 
evidence of genomic progression via point mutations in other genes, by 
rearrangements, or by genomic gains and losses. However, it also entirely possible 
that invasive behaviour may arise from pre-invasive lesions by dysregulation of 
epigenetic mechanisms. 
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Table legends 
Table 1. Breakdown of the values recorded for the scoring system developed to 
distinguish Noguchi C1 (precursor) and C2 (outgrowth) tumors. Total scores of 3 or 2 
were classified as ‘C1’, scores of 1 or 0 as ‘C2’.  
 
Table 2. Demographic and pathological characteristics of the Noguchi C patient 
cohort, when separated into C1 and C2 subtypes. 
 
Table 3. Breakdown of the Noguchi C1 (precursor) and C2 (outgrowth) tumors by 
current WHO classification of tumor subtype. 
 
Table 4. Summary of the two patterns of ‘precursor’ and ‘outgrowth’ in situ tumor 
pattern seen in Noguchi C1 and C2 tumors respectively. 
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Figure legends 
 
Figure 1. (A) Schematic representation of the morphological characteristics of C1 vs 
C2 tumors. C1 tumors show sporadic appearance of a high-grade invasive focus 
from a low-grade precursor and are often asymmetrical. As such the typical C1 is 
lepidic predominant with a minor invasive component, although tumors with any 
residual lower grade, non-symmetrical lepidic component would similarly be 
classified as C1 by our scoring.C2 tumors represent high-grade invasive carcinomas 
with peripheral lepidic spread (outgrowth) of invasive tumor cells. As C2 tumors have 
are expanding from a central invasive region, they show more symmetry, often with a 
marked constant-thickness ‘penumbra’ of in situ disease due to lepidic outgrowth. (B) 
Histology of representative C1 and C2 tumors. Low-power views show tumor 
architecture alongside high power regions from the in situ and invasive component of 
both tumors. (C) Lymph node positivity at resection by subtype. C2 tumors are more 
likely to show nodal metastasis than C1 tumors (p<0.01). (C) Kaplan-Meier plot of 5 
year overall survival of early lung adenocarcinoma patients in the LATTICe-A cohort 
– Noguchi A and B (biologically in situ), Noguchi C1, NoguchiC2 and a combined 
group of fully invasive subtypes (D). 
 
 
Figure 2. (A) Distribution of Ki67 index scoring on the C1 and C2 tissue microarray. 
C2 tumors show significantly higher proliferation index than C1 tumors. Also, C1 
tumors show a significant increase in proliferation from in situ to invasive disease 
which is not seen in C2 tumors. (B) Likewise positivity for p53 staining was 
significantly higher in C2 lesions overall and showed an increase from in situ to 
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invasive disease only within C1 lesions. (C) Studying mesenchymal Vimentin as a 
marker of epithelial mesenchymal transition within this cohort, expression increased 
significantly from in situ to invasive disease in C1 tumors only. 
 
Figure 3. Representative staining of in situ and invasive 1 mm diameter cores from 
the early adenocarcinoma LATTICe-A tissue microarray, for Ki67, p53 and Vimentin. 
These example cases show Ki67 which is of higher fraction in the invasive 
component for Ki67 staining. In the cores stained for p53 the in situ core is negative, 
with positivity in the invasive core. Vimentin expression is seen in only the stroma 
and alveolar macrophages in the in situ core, with tumor cell expression identified in 
the invasive core. 
Figure 4. Summary of the variants identified in C1 lesions and those C2 tumors for 
which DNA was extracted from both in situ and invasive tumor regions.  Green 
represents variants identified in both in situ and invasive regions of the tumor. Red 
represents variants private to the invasive region. Although cases were tested using 
a 22-gene next generation sequencing panel, variants in the 23 cases tested were 
only called in 7 of these genes, as represented. 
 
Figure 5. (A) Kernel plot demonstrating the distribution of Ki67 fraction in the in situ 
component from the LATTICe-A cohort. (B) Overall survival analysis over 5 years of 
756 cases from the entire LATTICe-A cohort with cases classified by the Ki67 
fraction in the invasive component of the tumor. (C) Overall survival analysis over 5 
years of 143 cases from the entire LATTICe-A cohort with cases classified by the 
Ki67 fraction in the in situ component of the tumor. 
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